Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma
-
- STATUS
- Recruiting
-
- participants needed
- 216
-
- sponsor
- National Cancer Institute (NCI)
Summary
- Background
-
- Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and
adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is
usually caused by a genetic mutation, and it can cause a number of problems in addition to
MTC. These problems include adrenal gland tumors, hormone changes, and problems with the
bones and other organs. Not much is known about how MTC develops over time, especially in
people with MEN2. Researchers want to study MTC in children and adults and see how it affects
their growth and development.
- Objectives
- To study how medullary thyroid cancer affects children and adults over time.
- Eligibility
- Children and adults who have medullary thyroid cancer.
- Design
- Participants will be screened with a brief physical exam and medical history. Blood and tissue samples will be collected to see whether participants have the MEN2 genetic mutation.
- Treatment will not be provided as part of this study. However, participants will be receiving standard care for MTC. They may be eligible for other clinical trials at the National Institutes of Health.
- Participants will have regular study visits every 6 to 12 months to evaluate their MTC and any treatment. Blood tests, imaging studies, and other tests may be performed as needed to monitor the disease.
- Participants and their parents/guardians will also complete questionnaires about their health and emotions during the study.
- Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and
adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is
usually caused by a genetic mutation, and it can cause a number of problems in addition to
MTC. These problems include adrenal gland tumors, hormone changes, and problems with the
bones and other organs. Not much is known about how MTC develops over time, especially in
people with MEN2. Researchers want to study MTC in children and adults and see how it affects
their growth and development.
Description
- Background
-
- Medullary Thyroid Carcinoma (MTC) is a calcitonin producing tumor arising from the parafollicular C cells of thyroid. In children and adults, MTC is usually seen in association with Multiple Endocrine Neoplasia (MEN) 2A and 2B, which are rare cancer syndromes resulting from germline mutations of Rearranged during Transfection (RET) proto-oncogene. MTC develops in virtually all patients with MEN 2, and is the leading cause of death in these patients. Patients with MEN 2 may have other characteristic manifestations such as pheochromocytoma and hyperparathyroidism in MEN 2A and pheochromocytoma, ganglioneuromatosis, and skeletal deformities in MEN 2B.
- Complete surgical resection is the only current curative treatment for MTC, and the tumor is unresponsive to standard chemotherapy and conventional doses of radiation therapy. However, more than half the patients present with advanced or metastatic disease and cannot be cured surgically. Novel agents are currently under investigation for treatment of MTC, and vandetanib, an oral RET and receptor tyrosine kinase (RTK) inhibitor was recently approved by the FDA for adults with advanced or metastatic MTC. Vandetanib also has activity in children with hereditary MTC.
- However, complete responses to RTKs have not been observed, and some patients develop
resistance to the treatment with RET and RTK inhibitors or have primary refractory
disease. The natural history of MTC, particularly in patients with MEN 2, the molecular
pathways involved in tumorigenesis, and the development of resistance to targeted
therapies are not well understood.
- Objectives
-The overall objective of this longitudinal study is to develop a better understanding of the biology and natural history of MEN2 with or without MTC, particularly in children and adults with MEN 2A and 2B, as well as study non-tumor manifestations of MEN 2. This will hopefully allow for developing more effective treatment interventions for tumor and non-tumor related manifestations, and more sensitive endpoints in clinical trials.
- Eligibility
-
- Patients, must have histologically or cytologically confirmed MTC, confirmed by the Laboratory of Pathology, NCI or who have MEN2 (regardless of MTC status).
- Parent or primary caregiver of patient participant (<= 21)
- Participants may be undergoing standard care or receiving treatment on a clinical trial while participating in this study.
- Design
This study will allow for longitudinal evaluations of MTC and MEN2 and non-tumor related manifestations of MEN 2A and 2B in children and adults. Evaluations will consist of the following (summarized):
- Clinical and radiological evaluations
- Detailed pathologic and molecular analysis of tumor specimens will be performed, including immunohistochemistry (IHC), comparative genomic hybridization (CGH), and genome sequencing. CGH and genome sequencing will be performd with co-enrollment on protocol 10-C-0086 Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies.
Details
| Condition | Medullary Thyroid Cancer |
|---|---|
| Clinical Study Identifier | NCT01660984 |
| Sponsor | National Cancer Institute (NCI) |
| Last Modified on | 24 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer